Immune control and failure in HCV infection—tipping the balance

Journal of Leukocyte Biology

Volumn 96, Issue 4, 2014, Pages 535-548

  Dustin, Lynn B ^a   Cashman, Siobhán B ^a   Laidlaw, Stephen M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

B lymphocytes; Immune evasion; Innate immunity; Interferons; NK cells; T lymphocytes

Indexed keywords

HEPATITIS C ANTIBODY; INTERFERON;

B LYMPHOCYTE; CELLULAR IMMUNITY; GENE EXPRESSION; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; NATURAL KILLER CELL; T LYMPHOCYTE;

B-LYMPHOCYTES; GENE EXPRESSION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INTERFERONS; KILLER CELLS, NATURAL; T-LYMPHOCYTES;

EID: 84907541219     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.4RI0214-126R     Document Type: Review

References (223)

1. Hajarizadeh, B., Grebely, J., Dore, G. J. (2013) Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 10, 553- 562.
2. Lavanchy, D. (2011) Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17, 107-115.
3. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., Wiersma, S. T. (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342.
4. Seeff, L. B. (2009) The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 29 (Suppl. 1), 89-99.
5. Ly, K. N., Xing, J., Klevens, R. M., Jiles, R. B., Ward, J. W., Holmberg, S. D. (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 156, 271- 278.
6. Ly, K. N., Xing, J., Klevens, R. M., Jiles, R. B., Holmberg, S. D. (2014) Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin. Infect. Dis. 58, 40-49.
7. Thomas, D. L., Leoutsakas, D., Zabransky, T., Kumar, M. S. (2011) Hepatitis C in HIV-infected individuals: cure and control, right now. J. Int. AIDS Soc. 14, 22.
8. Sagnelli, E., Pisaturo, M., Martini, S., Sagnelli, C., Filippini, P., Coppola, N. (2014) Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin. Pharmacother. 15, 1337-1349.
9. Kamal, S., Madwar, M., Bianchi, L., Tawil, A. E., Fawzy, R., Peters, T., Rasenack, J. W. (2000) Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 20, 281-289.
10. Tse, M. T. (2013) All-oral HCV therapies near approval. Nat. Rev. Drug Discov. 12, 409-411.
11. Volk, M. L., Tocco, R., Saini, S., Lok, A. S. (2009) Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50, 1750-1755.
12. Thomas, D. L. (2013) Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19, 850-858.
13. Aronsohn, A., Jensen, D. (2013) Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. Hepatology 59, 13-15.
14. Liang, T. J. (2013) Current progress in development of hepatitis C virus vaccines. Nat. Med. 19, 869-878.
15. Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T., Simmonds, P. (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59, 318-327.
16. Moradpour, D., Penin, F., Rice, C. M. (2007) Replication of hepatitis C virus. Nat. Rev. Microbiol. 5, 453-463.
17. Scheel, T. K., Rice, C. M. (2013) Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19, 837-849.
18. Bartenschlager, R., Lohmann, V., Penin, F. (2013) The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11, 482-496.
19. Shimizu, Y., Hishiki, T., Ujino, S., Sugiyama, K., Funami, K., Shimotohno, K. (2011) Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. Curr. Opin. Virol. 1, 19-26.
20. Lindenbach, B. D., Rice, C. M. (2013) The ins and outs of hepatitis C virus entry and assembly. Nat. Rev. Microbiol. 11, 688-700.
21. Wieland, S., Makowska, Z., Campana, B., Calabrese, D., Dill, M. T., Chung, J., Chisari, F. V., Heim, M. H. (2014) Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59, 2121-2130.
22. Palm, N. W., Medzhitov, R. (2009) Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227, 221-233.
23. Horner, S. M., Gale Jr., M. (2013) Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 19, 879-888.
24. Li, K., Lemon, S. M. (2013) Innate immune responses in hepatitis C virus infection. Semin. Immunopathol. 35, 53-72.
25. Major, M. E., Dahari, H., Mihalik, K., Puig, M., Rice, C. M., Neumann, A. U., Feinstone, S. M. (2004) Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39, 1709-1720.
26. Dahari, H., Major, M., Zhang, X., Mihalik, K., Rice, C. M., Perelson, A. S., Feinstone, S. M., Neumann, A. U. (2005) Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 128, 1056-1066.
27. Bigger, C. B., Brasky, K. M., Lanford, R. E. (2001) DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75, 7059-7066.
28. Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., Chisari, F. V. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 99, 15669-15674.
29. Thimme, R., Bukh, J., Spangenberg, H. C., Wieland, S., Pemberton, J., Steiger, C., Govindarajan, S., Purcell, R. H., Chisari, F. V. (2002) Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 99, 15661-15668.
30. Dixit, E., Kagan, J. C. (2013) Intracellular pathogen detection by RIG-Ilike receptors. Adv. Immunol. 117, 99-125.
31. Cui, S., Eisenacher, K., Kirchhofer, A., Brzozka, K., Lammens, A., Lammens, K., Fujita, T., Conzelmann, K. K., Krug, A., Hopfner, K. P. (2008) The C-terminal regulatory domain is the RNA 5′-triphosphate sensor of RIG-I. Mol. Cell 29, 169-179.
32. Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J., Gale Jr., M. (2008) Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523-527.
33. Uzri, D., Gehrke, L. (2009) Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J. Virol. 83, 4174-4184.
34. Gack, M. U., Shin, Y. C., Joo, C. H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., Jung, J. U. (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916-920.
35. Liu, S., Chen, J., Cai, X., Wu, J., Chen, X., Wu, Y.-T., Sun, L., Chen, Z. J., Shao, F. (2013) MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. Elfe 2, e00785.
36. Zinngrebe, J., Montinaro, A., Peltzer, N., Walczak, H. (2014) Ubiquitin in the immune system. EMBO Rep. 15, 28-45.
37. Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., Tschopp, J. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172.
38. Li, X. D., Sun, L., Seth, R. B., Pineda, G., Chen, Z. J. (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA 102, 17717-17722.
39. Bellecave, P., Sarasin-Filipowicz, M., Donze, O., Kennel, A., Gouttenoire, J., Meylan, E., Terracciano, L., Tschopp, J., Sarrazin, C., Berg, T., Moradpour, D., Heim, M. H. (2010) Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 51, 1127-1136.
40. Loo, Y. M., Owen, D. M., Li, K., Erickson, A. K., Johnson, C. L., Fish, P. M., Carney, D. S., Wang, T., Ishida, H., Yoneyama, M., Fujita, T., Saito, T., Lee, W. M., Hagedorn, C. H., Lau, D. T., Weinman, S. A., Lemon, S. M., Gale Jr., M. (2006) Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 103, 6001-6006.
41. Weber, M., Gawanbacht, A., Habjan, M., Rang, A., Borner, C., Schmidt, Anna M., Veitinger, S., Jacob, R., Devignot, S., Kochs, G., García-Sastre, A., Weber, F. (2013) Incoming RNA virus nucleocapsids containing a 5′-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe 13, 336-346.
42. Shimoike, T., McKenna, S. A., Lindhout, D. A., Puglisi, J. D. (2009) Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res. 83, 228-237.
43. Arnaud, N., Dabo, S., Akazawa, D., Fukasawa, M., Shinkai-Ouchi, F., Hugon, J., Wakita, T., Meurs, E. F. (2011) Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7, e1002289.
44. Garaigorta, U., Chisari, F. V. (2009) Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6, 513-522.
45. Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L. L., Coltescu, C., Heathcote, J., Edwards, A. M., McGilvray, I. D. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444.
46. Chen, L., Sun, J., Meng, L., Heathcote, J., Edwards, A. M., McGilvray, I. D. (2010) ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J. Gen. Virol. 91, 382-388.
47. Li, K., Foy, E., Ferreon, J. C., Nakamura, M., Ferreon, A. C., Ikeda, M., Ray, S. C., Gale Jr., M. Lemon, S. M. (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 102, 2992-2997.
48. Schoggins, J. W., Rice, C. M. (2013) Innate immune responses to hepatitis C virus. Curr. Top. Microbiol. Immunol. 369, 219-242.
49. Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., Donnelly, R. P. (2003) IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77.
50. Prokunina-Olsson, L., Muchmore, B., Tang, W., Pfeiffer, R. M., Park, H., Dickensheets, H., Hergott, D., Porter-Gill, P., Mumy, A., Kohaar, I., et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171.
51. Takahashi, K., Asabe, S., Wieland, S., Garaigorta, U., Gastaminza, P., Isogawa, M., Chisari, F. V. (2010) Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. USA 107, 7431-7436.
52. Dreux, M., Garaigorta, U., Boyd, B., Decembre, E., Chung, J., Whitten- Bauer, C., Wieland, S., Chisari, F. V. (2012) Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12, 558-570.
53. Stone, A. E., Giugliano, S., Schnell, G., Cheng, L., Leahy, K. F., Golden- Mason, L., Gale Jr., M., Rosen, H. R. (2013) Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of λ-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 9, e1003316.
54. Marukian, S., Andrus, L., Sheahan, T. P., Jones, C. T., Charles, E. D., Ploss, A., Rice, C. M., Dustin, L. B. (2011) Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 54, 1913-1923.
55. Park, H., Serti, E., Eke, O., Muchmore, B., Prokunina-Olsson, L., Capone, S., Folgori, A., Rehermann, B. (2012) IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56, 2060-2070.
56. Thomas, E., Gonzalez, V. D., Li, Q., Modi, A. A., Chen, W., Noureddin, M., Rotman, Y., Liang, T. J. (2012) HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142, 978-988.
57. Sheahan, T., Imanaka, N., Marukian, S., Dorner, M., Liu, P., Ploss, A., Rice, C. M. (2014) Interferon λ alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15, 190-202.
58. Andrus, L., Marukian, S., Jones, C. T., Catanese, M. T., Sheahan, T. P., Schoggins, J. W., Barry, W. T., Dustin, L. B., Trehan, K., Ploss, A., Bhatia, S. N., Rice, C. M. (2011) Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 54, 1901-1912.
59. Marcello, T., Grakoui, A., Barba-Spaeth, G., Machlin, E. S., Kotenko, S. V., MacDonald, M. R., Rice, C. M. (2006) Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887-1898.
60. Robek, M. D., Boyd, B. S., Chisari, F. V. (2005) λ Interferon inhibits hepatitis B and C virus replication. J. Virol. 79, 3851-3854.
61. Schoggins, J. W., Rice, C. M. (2011) Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1, 519-525.
62. Metz, P., Reuter, A., Bender, S., Bartenschlager, R. (2013) Interferonstimulated genes and their role in controlling hepatitis C virus. J. Hepatol. 59, 1331-1341.
63. Jilg, N., Lin, W., Hong, J., Schaefer, E. A., Wolski, D., Meixong, J., Goto, K., Brisac, C., Chusri, P., Fusco, D. N., et al. (2014) Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59, 1250-1261.
64. Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., Rice, C. M. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481- 485.
65. Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H., Christen, V., Terracciano, L., Filipowicz, W., Heim, M. H. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105, 7034-7039.
66. Urban, T. J., Thompson, A. J., Bradrick, S. S., Fellay, J., Schuppan, D., Cronin, K. D., Hong, L., McKenzie, A., Patel, K., Shianna, K. V., McHutchison, J. G., Goldstein, D. B., Afdhal, N. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon- stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888-1896.
67. Bauhofer, O., Ruggieri, A., Schmid, B., Schirmacher, P., Bartenschlager, R. (2012) Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 143, 429-438.e8.
68. Kandathil, A. J., Graw, F., Quinn, J., Hwang, H. S., Torbenson, M., Perelson, A. S., Ray, S. C., Thomas, D. L., Ribeiro, R. M., Balagopal, A. (2013) Use of laser capture microdissection to map hepatitis C viruspositive hepatocytes in human liver. Gastroenterology 145, 1404- 1413.e10.
69. Heathcote, E. J. (2007) Antiviral therapy: chronic hepatitis C. J. Viral. Hepat. 14 (Suppl. 1), 82-88.
70. Charles, E. D., Dustin, L. B. (2011) Chemokine antagonism in chronic hepatitis C virus infection. J. Clin. Invest. 121, 25-27.
71. Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., Sulkowski, M., McHutchison, J. G., Goldstein, D. B. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401.
72. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli, V., Muller, T., Bahlo, M., Stewart, G. J., Booth, D. R., George, J. (2009) IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100-1104.
73. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109.
74. Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O'huigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-802.
75. Aka, P. V., Kuniholm, M. H., Pfeiffer, R. M., Wang, A. S., Tang, W., Chen, S., Astemborski, J., Plankey, M., Villacres, M. C., Peters, M. G., et al. (2014) Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus. J. Infect. Dis. 209, 350-354.
76. Jouvin-Marche, E., Macek Jilkova, Z., Thelu, M. A., Marche, H., Fugier, E., Van Campenhout, N., Hoang, X. S., Marlu, A., Sturm, N., Callanan, M., Leroy, V., Zarski, J. P., Marche, P. N. (2014) Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. J. Infect. Dis. 209, 1907-1915.
77. Amanzada, A., Kopp, W., Spengler, U., Ramadori, G., Mihm, S. (2013) Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples. PLoS One 8, e84026.
78. Racanelli, V., Rehermann, B. (2006) The liver as an immunological organ. Hepatology 43, S54-62.
79. Cheent, K., Khakoo, S. I. (2011) Natural killer cells and hepatitis C: action and reaction. Gut 60, 268-278.
80. Long, E. O., Kim, H. S., Liu, D., Peterson, M. E., Rajagopalan, S. (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31, 227-258.
81. Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., Ugolini, S. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49.
82. Khakoo, S. I., Thio, C. L., Martin, M. P., Brooks, C. R., Gao, X., Astemborski, J., Cheng, J., Goedert, J. J., Vlahov, D., Hilgartner, M., Cox, S., Little, A. M., Alexander, G. J., Cramp, M. E., O'Brien, S. J., Rosenberg, W. M., Thomas, D. L., Carrington, M. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872-874.
83. Knapp, S., Warshow, U., Hegazy, D., Brackenbury, L., Guha, I. N., Fowell, A., Little, A. M., Alexander, G. J., Rosenberg, W. M., Cramp, M. E., Khakoo, S. I. (2010) Consistent beneficial effects of killer cell immunoglobulin- like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51, 1168-1175.
84. Dustin, L. B., Rice, C. M. (2007) Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25, 71-99.
85. Amadei, B., Urbani, S., Cazaly, A., Fisicaro, P., Zerbini, A., Ahmed, P., Missale, G., Ferrari, C., Khakoo, S. I. (2010) Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138, 1536-1545.
86. Pelletier, S., Drouin, C., Bedard, N., Khakoo, S. I., Bruneau, J., Shoukry, N. H. (2010) Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J. Hepatol. 53, 805-816.
87. Yoon, J. C., Shiina, M., Ahlenstiel, G., Rehermann, B. (2009) Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49, 12-21.
88. Edlich, B., Ahlenstiel, G., Zabaleta Azpiroz, A., Stoltzfus, J., Noureddin, M., Serti, E., Feld, J. J., Liang, T. J., Rotman, Y., Rehermann, B. (2012) Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 55, 39-48.
89. Golden-Mason, L., Rosen, H. R. (2013) Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol. Rev. 255, 68-81.
90. Stegmann, K. A., Bjorkstrom, N. K., Veber, H., Ciesek, S., Riese, P., Wiegand, J., Hadem, J., Suneetha, P. V., Jaroszewicz, J., Wang, C., Schlaphoff, V., Fytili, P., Cornberg, M., Manns, M. P., Geffers, R., Pietschmann, T., Guzman, C. A., Ljunggren, H. G., Wedemeyer, H. (2010) Interferon-α-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138, 1885-1897.
91. Rehermann, B. (2009) Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119, 1745-1754.
92. Rehermann, B. (2013) Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat. Med. 19, 859-868.
93. + T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76, 12584-12595.
94. Grakoui, A., Shoukry, N. H., Woollard, D. J., Han, J. H., Hanson, H. L., Ghrayeb, J., Murthy, K. K., Rice, C. M., Walker, C. M. (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659-662.
95. + T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197, 1645-1655.
96. Jo, J., Aichele, U., Kersting, N., Klein, R., Aichele, P., Bisse, E., Sewell, A. K., Blum, H. E., Bartenschlager, R., Lohmann, V., Thimme, R. (2009) Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136, 1391-1401.
97. Watanabe, H., Wells, F., Major, M. E. (2010) Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase. J. Viral. Hepat. 17, 245-253.
98. Wherry, E. J. (2011) T cell exhaustion. Nat. Immunol. 12, 492-499.
99. Mehta, S. H., Cox, A., Hoover, D. R., Wang, X. H., Mao, Q., Ray, S., Strathdee, S. A., Vlahov, D., Thomas, D. L. (2002) Protection against persistence of hepatitis C. Lancet 359, 1478-1483.
100. Lanford, R. E., Guerra, B., Chavez, D., Bigger, C., Brasky, K. M., Wang, X. H., Ray, S. C., Thomas, D. L. (2004) Cross-genotype immunity to hepatitis C virus. J. Virol. 78, 1575-1581.
101. Bukh, J., Thimme, R., Meunier, J. C., Faulk, K., Spangenberg, H. C., Chang, K. M., Satterfield, W., Chisari, F. V., Purcell, R. H. (2008) Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82, 8183-8195.
102. Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H., Ogata, N., et al. (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258, 135-140.
103. Schulze Zur Wiesch, J., Lauer, G. M., Timm, J., Kuntzen, T., Neukamm, M., Berical, A., Jones, A. M., Nolan, B. E., Longworth, S. A., Kasprowicz, V., et al. (2007) Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with nongenotype 1 infection. Blood 110, 1559-1569.
104. Park, S. H., Veerapu, N. S., Shin, E. C., Biancotto, A., McCoy, J. P., Capone, S., Folgori, A., Rehermann, B. (2013) Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat. Med. 19, 1638-1642.
105. Thimme, R., Oldach, D., Chang, K. M., Steiger, C., Ray, S. C., Chisari, F. V. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194, 1395-1406.
106. Klenerman, P., Thimme, R. (2012) T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 61, 1226-1234.
107. Guidotti, L. G., Chisari, F. V. (2006) Imunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. Mech. Dis. 1, 23-61.
108. Kakimi, K., Lane, T. E., Wieland, S., Asensio, V. C., Campbell, I. L., Chisari, F. V., Guidotti, L. G. (2001) Blocking chemokine responsive to γ-2/interferon (IFN)-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755-1766.
109. Raghuraman, S., Park, H., Osburn, W. O., Winkelstein, E., Edlin, B. R., Rehermann, B. (2012) Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J. Infect. Dis. 205, 763-771.
110. Callendret, B., Walker, C. (2011) A siege of hepatitis: immune boost for viral hepatitis. Nat. Med. 17, 252-253.
111. Day, C. L., Seth, N. P., Lucas, M., Appel, H., Gauthier, L., Lauer, G. M., Robbins, G. K., Szczepiorkowski, Z. M., Casson, D. R., Chung, R. T., Bell, S., Harcourt, G., Walker, B. D., Klenerman, P., Wucherpfennig, K. W. (2003) Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. 112, 831-842.
112. + T-cell response in acute hepatitis C. Gastroenterology 117, 933-941.
113. Schulze Zur Wiesch, J., Ciuffreda, D., Lewis-Ximenez, L., Kasprowicz, V., Nolan, B. E., Streeck, H., Aneja, J., Reyor, L. L., Allen, T. M., Lohse, A. W., McGovern, B., Chung, R. T., Kwok, W. W., Kim, A. Y., Lauer, G. M. (2012) Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J. Exp. Med. 209, 61- 75.
114. Welsh, R. M., Waggoner, S. N. (2013) NK cells controlling virus-specific T cells: rheostats for acute vs. persistent infections. Virology 435, 37-45.
115. Waggoner, S. N., Daniels, K. A., Welsh, R. M. (2014) Therapeutic depletion of natural killer cells controls persistent infection. J. Virol. 88, 1953-1960.
116. Fuller, M. J., Shoukry, N. H., Gushima, T., Bowen, D. G., Callendret, B., Campbell, K. J., Hasselschwert, D. L., Hughes, A. L., Walker, C. M. (2010) Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 51, 378-387.
117. Fleming, V. M., Harcourt, G., Barnes, E., Klenerman, P. (2010) Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. J. Gen. Virol. 91, 1396-1406.
118. Golden-Mason, L., Burton J. R., Jr., Castelblanco, N., Klarquist, J., Benlloch, S., Wang, C., Rosen, H. R. (2006) Loss of IL-7 receptor α-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 44, 1098-1109.
119. McMahan, R. H., Golden-Mason, L., Nishimura, M. I., McMahon, B. J., Kemper, M., Allen, T. M., Gretch, D. R., Rosen, H. R. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 120, 4546-4557.
120. Raziorrouh, B., Ulsenheimer, A., Schraut, W., Heeg, M., Kurktschiev, P., Zachoval, R., Jung, M. C., Thimme, R., Neumann-Haefelin, C., Horster, S., Wachtler, M., Spannagl, M., Haas, J., Diepolder, H. M., Gruner, N. H. (2011) Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 141, 1422-1431, 1431.e1-1431.e6.
121. Kared, H., Fabre, T., Bedard, N., Bruneau, J., Shoukry, N. H. (2013) Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog. 9, e1003422.
122. Bengsch, B., Seigel, B., Ruhl, M., Timm, J., Kuntz, M., Blum, H. E., Pircher, H., Thimme, R. (2010) Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947.
123. Radziewicz, H., Ibegbu, C. C., Fernandez, M. L., Workowski, K. A., Obideen, K., Wehbi, M., Hanson, H. L., Steinberg, J. P., Masopust, D., Wherry, E. J., Altman, J. D., Rouse, B. T., Freeman, G. J., Ahmed, R., Grakoui, A. (2007) Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81, 2545- 2553.
124. Golden-Mason, L., Palmer, B. E., Kassam, N., Townshend-Bulson, L., Livingston, S., McMahon, B. J., Castelblanco, N., Kuchroo, V., Gretch, D. R., Rosen, H. R. (2009) Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 83, 9122-9130.
125. Kroy, D. C., Ciuffreda, D., Cooperrider, J. H., Tomlinson, M., Hauck, G. D., Aneja, J., Berger, C., Wolski, D., Carrington, M., Wherry, E. J., Chung, R. T., Tanabe, K. K., Elias, N., Freeman, G. J., de Kruyff, R. H., Misdraji, J., Kim, A. Y., Lauer, G. M. (2014) Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146, 550-561.
126. Zhang, N., Bevan, M. J. (2011) CD8(+) T cells: foot soldiers of the immune system. Immunity 35, 161-168.
127. Cox, M. A., Harrington, L. E., Zajac, A. J. (2011) Cytokines and the inception of CD8 T cell responses. Trends Immunol. 32, 180-186.
128. Radziewicz, H., Ibegbu, C. C., Hon, H., Osborn, M. K., Obideen, K., Wehbi, M., Freeman, G. J., Lennox, J. L., Workowski, K. A., Hanson, H. L., Grakoui, A. (2008) Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J. Virol. 82, 9808-9822.
129. Park, S. H., Shin, E. C., Capone, S., Caggiari, L., De Re, V., Nicosia, A., Folgori, A., Rehermann, B. (2012) Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 143, 1048-1060.e4.
130. Rong, L., Dahari, H., Ribeiro, R. M., Perelson, A. S. (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2, 30-32.
131. Erickson, A. L., Kimura, Y., Igarashi, S., Eichelberger, J., Houghton, M., Sidney, J., McKinney, D., Sette, A., Hughes, A. L., Walker, C. M. (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883-895.
132. Timm, J., Lauer, G. M., Kavanagh, D. G., Sheridan, I., Kim, A. Y., Lucas, M., Pillay, T., Ouchi, K., Reyor, L. L., Zur Wiesch, J. S., Gandhi, R. T., Chung, R. T., Bhardwaj, N., Klenerman, P., Walker, B. D., Allen, T. M. (2004) CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 200, 1593-1604.
133. Cox, A. L., Mosbruger, T., Mao, Q., Liu, Z., Wang, X. H., Yang, H. C., Sidney, J., Sette, A., Pardoll, D., Thomas, D. L., Ray, S. C. (2005) Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201, 1741-1752.
134. Tester, I., Smyk-Pearson, S., Wang, P., Wertheimer, A., Yao, E., Lewinsohn, D. M., Tavis, J. E., Rosen, H. R. (2005) Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med. 201, 1725-1731.
135. Komatsu, H., Lauer, G., Pybus, O. G., Ouchi, K., Wong, D., Ward, S., Walker, B., Klenerman, P. (2006) Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes. J. Viral Hepat. 13, 121-130.
136. Neumann-Haefelin, C., McKiernan, S., Ward, S., Viazov, S., Spangenberg, H. C., Killinger, T., Baumert, T. F., Nazarova, N., Sheridan, I., Pybus, O., von Weizsacker, F., Roggendorf, M., Kelleher, D., Klenerman, P., Blum, H. E., Thimme, R. (2006) Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43, 563-572.
137. Fitzmaurice, K., Petrovic, D., Ramamurthy, N., Simmons, R., Merani, S., Gaudieri, S., Sims, S., Dempsey, E., Freitas, E., Lea, S., McKiernan, S., Norris, S., Long, A., Kelleher, D., Klenerman, P. (2011) Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 60, 1563-1571.
138. Merani, S., Petrovic, D., James, I., Chopra, A., Cooper, D., Freitas, E., Rauch, A., di Iulio, J., John, M., Lucas, M., Fitzmaurice, K., McKiernan, S., Norris, S., Kelleher, D., Klenerman, P., Gaudieri, S. (2011) Effect of immune pressure on hepatitis C virus evolution: insights from a singlesource outbreak. Hepatology 53, 396-405.
139. Meyer-Olson, D., Shoukry, N. H., Brady, K. W., Kim, H., Olson, D. P., Hartman, K., Shintani, A. K., Walker, C. M., Kalams, S. A. (2004) Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J. Exp. Med. 200, 307-319.
140. Wolfl, M., Rutebemberwa, A., Mosbruger, T., Mao, Q., Li, H. M., Netski, D., Ray, S. C., Pardoll, D., Sidney, J., Sette, A., Allen, T., Kuntzen, T., Kavanagh, D. G., Kuball, J., Greenberg, P. D., Cox, A. L. (2008) Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181, 6435-6446.
141. Chang, K. M., Rehermann, B., McHutchison, J. G., Pasquinelli, C., Southwood, S., Sette, A., Chisari, F. V. (1997) Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100, 2376-2385.
142. Ulsenheimer, A., Paranhos-Baccala, G., Komurian-Pradel, F., Raziorrouh, B., Kurktschiev, P., Diepolder, H. M., Zachoval, R., Spannagl, M., Jung, M. C., Gruener, N. H. (2013) Lack of variant specific CD8+ Tcell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C. Virol. J. 10, 295.
143. Fernandez, J., Taylor, D., Morhardt, D. R., Mihalik, K., Puig, M., Rice, C. M., Feinstone, S. M., Major, M. E. (2004) Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J. Virol. 78, 9782-9789.
144. Soderholm, J., Ahlen, G., Kaul, A., Frelin, L., Alheim, M., Barnfield, C., Liljestrom, P., Weiland, O., Milich, D. R., Bartenschlager, R., Sallberg, M. (2006) Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55, 266-274.
145. Neumann-Haefelin, C., Killinger, T., Timm, J., Southwood, S., McKinney, D., Blum, H. E., Thimme, R. (2007) Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. J. Gen. Virol. 88, 1986-1991.
146. Uebelhoer, L., Han, J. H., Callendret, B., Mateu, G., Shoukry, N. H., Hanson, H. L., Rice, C. M., Walker, C. M., Grakoui, A. (2008) Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 4, e1000143.
147. Dazert, E., Neumann-Haefelin, C., Bressanelli, S., Fitzmaurice, K., Kort, J., Timm, J., McKiernan, S., Kelleher, D., Gruener, N., Tavis, J. E., Rosen, H. R., Shaw, J., Bowness, P., Blum, H. E., Klenerman, P., Bartenschlager, R., Thimme, R. (2009) Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLAB27- restricted human immune response. J. Clin. Invest. 119, 376-386.
148. Pfafferott, K., Gaudieri, S., Ulsenheimer, A., James, I., Heeg, M., Nolan, D., John, M., Rauch, A., Mallal, S., Lucas, A., Klenerman, P., Diepolder, H. M., Lucas, M. (2011) Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One 6, e16797.
149. Kuntzen, T., Timm, J., Berical, A., Lewis-Ximenez, L. L., Jones, A., Nolan, B., Schulze zur Wiesch, J., Li, B., Schneidewind, A., Kim, A. Y., Chung, R. T., Lauer, G. M., Allen, T. M. (2007) Viral sequence evolution in acute hepatitis C virus infection. J. Virol. 81, 11658-11668.
150. Honegger, J. R., Kim, S., Price, A. A., Kohout, J. A., McKnight, K. L., Prasad, M. R., Lemon, S. M., Grakoui, A., Walker, C. M. (2013) Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat. Med. 19, 1529-1533.
151. Urbani, S., Amadei, B., Cariani, E., Fisicaro, P., Orlandini, A., Missale, G., Ferrari, C. (2005) The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection. J. Immunol. 175, 7519-7529.
152. Rutebemberwa, A., Ray, S. C., Astemborski, J., Levine, J., Liu, L., Dowd, K. A., Clute, S., Wang, C., Korman, A., Sette, A., Sidney, J., Pardoll, D. M., Cox, A. L. (2008) High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 181, 8215-8225.
153. Kasprowicz, V., Kang, Y. H., Lucas, M., Schulze zur Wiesch, J., Kuntzen, T., Fleming, V., Nolan, B. E., Longworth, S., Berical, A., Bengsch, B., Thimme, R., Lewis-Ximenez, L., Allen, T. M., Kim, A. Y., Klenerman, P., Lauer, G. M. (2010) Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. J. Virol. 84, 1656-1663.
154. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., Ahmed, R. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682- 687.
155. Frebel, H., Nindl, V., Schuepbach, R. A., Braunschweiler, T., Richter, K., Vogel, J., Wagner, C. A., Loffing-Cueni, D., Kurrer, M., Ludewig, B., Oxenius, A. (2012) Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 209, 2485- 2499.
156. Frebel, H., Oxenius, A. (2013) The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Trends Immunol. 34, 193-199.
157. Bowen, D. G., Shoukry, N. H., Grakoui, A., Fuller, M. J., Cawthon, A. G., Dong, C., Hasselschwert, D. L., Brasky, K. M., Freeman, G. J., Seth, N. P., Wucherpfennig, K. W., Houghton, M., Walker, C. M. (2008) Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J. Virol. 82, 5109-5114.
158. Nakamoto, N., Kaplan, D. E., Coleclough, J., Li, Y., Valiga, M. E., Kaminski, M., Shaked, A., Olthoff, K., Gostick, E., Price, D. A., Freeman, G. J., Wherry, E. J., Chang, K-M. (2008) Functional restoration of HCVspecific CD8 T cells by PD-1 blockade Is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927-1937.e2.
159. Fuller, M. J., Callendret, B., Zhu, B., Freeman, G. J., Hasselschwert, D. L., Satterfield, W., Sharpe, A. H., Dustin, L. B., Rice, C. M., Grakoui, A., Ahmed, R., Walker, C. M. (2013) Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc. Natl. Acad. Sci. USA 110, 15001-15006.
160. Nakamoto, N., Cho, H., Shaked, A., Olthoff, K., Valiga, M. E., Kaminski, M., Gostick, E., Price, D. A., Freeman, G. J., Wherry, E. J., Chang, K. M. (2009) Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313.
161. Netski, D. M., Mosbruger, T., Depla, E., Maertens, G., Ray, S. C., Hamilton, R. G., Roundtree, S., Thomas, D. L., McKeating, J., Cox, A. (2005) Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 41, 667-675.
162. Dustin, L. B., Charles, E. D. (2012) Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. Antivir. Ther. 17, 1449-1452.
163. Bassett, S. E., Thomas, D. L., Brasky, K. M., Lanford, R. E. (1999) Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J. Virol. 73, 1118-1126.
164. Cooper, S., Erickson, A. L., Adams, E. J., Kansopon, J., Weiner, A. J., Chien, D. Y., Houghton, M., Parham, P., Walker, C. M. (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439-449.
165. Razvi, S., Schneider, L., Jonas, M. M., Cunningham-Rundles, C. (2001) Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin. Immunol. 101, 284-288.
166. Logvinoff, C., Major, M. E., Oldach, D., Heyward, S., Talal, A., Balfe, P., Feinstone, S. M., Alter, H., Rice, C. M., McKeating, J. A. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 101, 10149-10154.
167. Major, M. E., Mihalik, K., Puig, M., Rehermann, B., Nascimbeni, M., Rice, C. M., Feinstone, S. M. (2002) Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76, 6586-6595.
168. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., Miller, J. L., Manns, M. P., Rehermann, B. (2000) Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6, 578-582.
169. Pestka, J. M., Zeisel, M. B., Blaser, E., Schurmann, P., Bartosch, B., Cosset, F. L., Patel, A. H., Meisel, H., Baumert, J., Viazov, S., Rispeter, K., Blum, H. E., Roggendorf, M., Baumert, T. F. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104, 6025-6030.
170. Osburn, W. O., Fisher, B. E., Dowd, K. A., Urban, G., Liu, L., Ray, S. C., Thomas, D. L., Cox, A. L. (2010) Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138, 315-324.
171. Bartosch, B., Bukh, J., Meunier, J. C., Granier, C., Engle, R. E., Blackwelder, W. C., Emerson, S. U., Cosset, F. L., Purcell, R. H. (2003) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. USA 100, 14199-14204.
172. Kaplan, D. E., Sugimoto, K., Newton, K., Valiga, M. E., Ikeda, F., Aytaman, A., Nunes, F. A., Lucey, M. R., Vance, B. A., Vonderheide, R. H., Reddy, K. R., McKeating, J. A., Chang, K. M. (2007) Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132, 654-666.
173. Farci, P., Alter, H. J., Wong, D. C., H., M. R., Govindarajan, S., Engle, R., Shapiro, M., Purcell, R. H. (1994) Prevention of hepatitis C virus infection in chimpanzee after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 91, 7792-7796.
174. Yu, M-y. W., Bartosch, B., Zhang, P., Guo, Z-p., Renzi, P. M., Shen, L-m., Granier, C., Feinstone, S. M., Cosset, F-L., Purcell, R. H. (2004) Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl. Acad. Sci. USA 101, 7705-7710.
175. Vanwolleghem, T., Bukh, J., Meuleman, P., Desombere, I., Meunier, J. C., Alter, H., Purcell, R. H., Leroux-Roels, G. (2008) Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47, 1846-1855.
176. Wahid, A., Dubuisson, J. (2013) Virus-neutralizing antibodies to hepatitis C virus. J. Viral. Hepat. 20, 369-376.
177. Zhang, P., Wu, C. G., Mihalik, K., Virata-Theimer, M. L., Yu, M. Y., Alter, H. J., Feinstone, S. M. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. USA 104, 8449-8454.
178. Zhang, P., Zhong, L., Struble, E. B., Watanabe, H., Kachko, A., Mihalik, K., Virata-Theimer, M. L., Alter, H. J., Feinstone, S., Major, M. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl. Acad. Sci. USA 106, 7537-7541.
179. Keck, Z., Wang, W., Wang, Y., Lau, P., Carlsen, T. H., Prentoe, J., Xia, J., Patel, A. H., Bukh, J., Foung, S. K. (2013) Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J. Virol. 87, 37-51.
180. Duan, H., Kachko, A., Zhong, L., Struble, E., Pandey, S., Yan, H., Harman, C., Virata-Theimer, M. L., Deng, L., Zhao, Z., Major, M., Feinstone, S., Zhang, P. (2012) Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein. J. Virol. 86, 12686-12694.
181. Helle, F., Duverlie, G., Dubuisson, J. (2011) The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses 3, 1909-1932.
182. Catanese, M. T., Uryu, K., Kopp, M., Edwards, T. J., Andrus, L., Rice, W. J., Silvestry, M., Kuhn, R. J., Rice, C. M. (2013) Ultrastructural analysis of hepatitis C virus particles. Proc. Natl. Acad. Sci. USA 110, 9505- 9510.
183. Timpe, J. M., Stamataki, Z., Jennings, A., Hu, K., Farquhar, M. J., Harris, H. J., Schwarz, A., Desombere, I., Roels, G. L., Balfe, P., McKeating, J. A. (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47, 17-24.
184. Liang, Y., Shilagard, T., Xiao, S. Y., Snyder, N., Lau, D., Cicalese, L., Weiss, H., Vargas, G., Lemon, S. M. (2009) Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137, 1448-1458.
185. Brimacombe, C. L., Grove, J., Meredith, L. W., Hu, K., Syder, A. J., Flores, M. V., Timpe, J. M., Krieger, S. E., Baumert, T. F., Tellinghuisen, T. L., Wong-Staal, F., Balfe, P., McKeating, J. A. (2011) Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85, 596-605.
186. Ramakrishnaiah, V., Thumann, C., Fofana, I., Habersetzer, F., Pan, Q., de Ruiter, P. E., Willemsen, R., Demmers, J. A., Stalin Raj, V., Jenster, G., Kwekkeboom, J., Tilanus, H. W., Haagmans, B. L., Baumert, T. F., van der Laan, L. J. (2013) Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. USA 110, 13109-13113.
187. Catanese, M. T., Loureiro, J., Jones, C. T., Dorner, M., von Hahn, T., Rice, C. M. (2013) Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J. Virol. 87, 8282-8293.
188. Bankwitz, D., Steinmann, E., Bitzegeio, J., Ciesek, S., Friesland, M., Herrmann, E., Zeisel, M. B., Baumert, T. F., Keck, Z. Y., Foung, S. K., Pecheur, E. I., Pietschmann, T. (2010) Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84, 5751- 5763.
189. Prentoe, J., Jensen, T. B., Meuleman, P., Serre, S. B., Scheel, T. K., Leroux- Roels, G., Gottwein, J. M., Bukh, J. (2011) Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 85, 2224-2234.
190. Von Hahn, T., Yoon, J. C., Alter, H., Rice, C. M., Rehermann, B., Balfe, P., McKeating, J. A. (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667-678.
191. Dowd, K. A., Netski, D. M., Wang, X. H., Cox, A. L., Ray, S. C. (2009) Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136, 2377-2386.
192. Liu, L., Fisher, B. E., Dowd, K. A., Astemborski, J., Cox, A. L., Ray, S. C. (2010) Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J. Virol. 84, 5067-5077.
193. Booth, J. C., Kumar, U., Webster, D., Monjardino, J., Thomas, H. C. (1998) Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27, 223-227.
194. Lee, W. M., Polson, J. E., Carney, D. S., Sahin, B., Gale Jr., M. (2005) Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J. Infect. Dis. 192, 1088-1092.
195. Gaud, U., Langer, B., Petropoulou, T., Thomas, H. C., Karayiannis, P. (2003) Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J. Med. Virol. 69, 350-356.
196. Kong, L., Giang, E., Nieusma, T., Kadam, R. U., Cogburn, K. E., Hua, Y., Dai, X., Stanfield, R. L., Burton, D. R., Ward, A. B., Wilson, I. A., Law, M. (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090-1094.
197. Goffard, A., Callens, N., Bartosch, B., Wychowski, C., Cosset, F. L., Montpellier, C., Dubuisson, J. (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79, 8400- 8409.
198. Helle, F., Vieyres, G., Elkrief, L., Popescu, C. I., Wychowski, C., Descamps, V., Castelain, S., Roingeard, P., Duverlie, G., Dubuisson, J. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 84, 11905-11915.
199. Falkowska, E., Kajumo, F., Garcia, E., Reinus, J., Dragic, T. (2007) Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81, 8072-8079.
200. Helle, F., Goffard, A., Morel, V., Duverlie, G., McKeating, J., Keck, Z. Y., Foung, S., Penin, F., Dubuisson, J., Voisset, C. (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81, 8101-8111.
201. Mayo, M. J. (2003) Extrahepatic manifestations of hepatitis C infection. Am. J. Med. Sci. 325, 135-148.
202. Giordano, T. P., Henderson, L., Landgren, O., Chiao, E. Y., Kramer, J. R., El-Serag, H., Engels, E. A. (2007) Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297, 2010-2017.
203. Charles, E. D., Dustin, L. B. (2009) Hepatitis C virus-induced cryoglobulinemia. Kidney Int. 76, 818-824.
204. Ramos-Casals, M., Stone, J. H., Cid, M. C., Bosch, X. (2012) The cryoglobulinaemias. Lancet 379, 348-360.
205. Peveling-Oberhag, J., Arcaini, L., Hansmann, M. L., Zeuzem, S. (2013) Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J. Hepatol. 59, 169-177.
206. Charles, E. D., Green, R. M., Marukian, S., Talal, A. H., Lake-Bakaar, G. V., Jacobson, I. M., Rice, C. M., Dustin, L. B. (2008) Clonal expansion of IgM+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 111, 1344-1356.
207. Visentini, M., Conti, V., Cristofoletti, C., Lazzeri, C., Marrapodi, R., Russo, G., Casato, M., Fiorilli, M. (2013) Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: the yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmun. Rev. 12, 430-435.
208. low B-cell subset. Blood 117, 5425-5437.
209. Chan, C. H., Hadlock, K. G., Foung, S. K., Levy, S. (2001) V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97, 1023-1026.
210. Marasca, R., Vaccari, P., Luppi, M., Zucchini, P., Castelli, I., Barozzi, P., Cuoghi, A., Torelli, G. (2001) Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am. J. Pathol. 159, 253-261.
211. De Re, V., De Vita, S., Marzotto, A., Gloghini, A., Pivetta, B., Gasparotto, D., Cannizzaro, R., Carbone, A., Boiocchi, M. (2000) Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigendriven pathological process. Intl. J. Cancer 87, 211-216.
212. Terrier, B., Joly, F., Vazquez, T., Benech, P., Rosenzwajg, M., Carpentier, W., Garrido, M., Ghillani-Dalbin, P., Klatzmann, D., Cacoub, P., Saadoun, D. (2011) Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J. Immunol. 187, 6550-6563.
213. L kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91, 2433-2442.
214. Rosa, D., Saletti, G., De Gregorio, E., Zorat, F., Comar, C., D'Oro, U., Nuti, S., Houghton, M., Barnaba, V., Pozzato, G., Abrignani, S. (2005) Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc. Natl. Acad. Sci. USA 102, 18544-18549.
215. Sung, V. M., Shimodaira, S., Doughty, A. L., Picchio, G. R., Can, H., Yen, T. S., Lindsay, K. L., Levine, A. M., Lai, M. M. (2003) Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J. Virol. 77, 2134-2146.
216. Marukian, S., Jones, C. T., Andrus, L., Evans, M. J., Ritola, K. D., Charles, E. D., Rice, C. M., Dustin, L. B. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48, 1843-1850.
217. McKeating, J. A., Zhang, L. Q., Logvinoff, C., Flint, M., Zhang, J., Yu, J., Butera, D., Ho, D. D., Dustin, L. B., Rice, C. M., Balfe, P. (2004) Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81 dependent manner. J. Virol. 78, 8496-8505.
218. Zehender, G., Meroni, L., De Maddalena, C., Varchetta, S., Monti, G., Galli, M. (1997) Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J. Infect. Dis. 176, 1209-1214.
219. Mellor, J., Haydon, G., Blair, C., Livingstone, W., Simmonds, P. (1998) Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J. Gen. Virol. 79, 705-714.
220. Pham, T. N., King, D., Macparland, S. A., McGrath, J. S., Reddy, S. B., Bursey, F. R., Michalak, T. I. (2008) Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 134, 812-822.
221. Veerapu, N. S., Raghuraman, S., Liang, T. J., Heller, T., Rehermann, B. (2011) Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 140, 676-685.e1.
222. Charles, E. D., Orloff, M. I., Nishiuchi, E., Marukian, S., Rice, C. M., Dustin, L. B. (2013) Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum. 65, 2430-2440.
223. Sène, D., Limal, N., Ghillani-Dalbin, P., Saadoun, D., Piette, J. C., Cacoub, P. (2007) Hepatitis C virus-associated B-cell proliferation—the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 46, 65-69.